Pfizer releases Paloma-2 sub-analysis study data
The sub-analysis studied Asian patients participating in the trial and showed that the combination significantly extended progression-free survival (PFS).
The Ibrance-letrozole combination was evaluated for the first-line treatment of women who are postmenopausal and estrogen receptor-positive.
“It is exciting to see that the significant efficacy shown in the Paloma-2 trial extends to Asian patients, further supporting the potential for Ibrance to be a standard of care treatment in Asia Pacific, a region where more than 600,000 women are affected by breast cancer each year,” Pfizer Oncology Regional Medical Lead Dr. Mahmood Alam said.
Data from the sub-analysis from the phase 3 Paloma-2 trial was presented at the second ESMO Asia Congress in Singapore.
“Across the Asia Pacific region, breast cancer has grown into a major health concern, with significant increases in breast cancer incidence in recent years in several Asian countries,” Dr. Seock-Ah Im, who works at the Seoul National University Hospital, said. “Patients with metastatic breast cancer, in particular those in Asia, eagerly await new and innovative treatment options.”
Organizations in this story
Pfizer 235 E 42nd St New York, NY 10017-5703